Browse by author
Lookup NU author(s): Dr Toni Pringle, Dr Corey ChanORCiD, Dr Saimir LuliORCiD, Dr Helen Blair, Dr Kenneth RankinORCiD, Dr James KnightORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
Bone sarcomas are devastating primary bone cancers that mostly affect children, young adults, and the elderly. These aggressive tumors are associated with poor survival, and surgery remains the mainstay of treatment. Surgical planning is increasingly informed by positron emission tomography (PET), and tumor margin identification during surgery is aided by near-infrared fluorescence (NIRF) imaging, yet these investigations are confounded by probes that lack specificity for sarcoma biomarkers. We report the development of a dual-modal (PET/NIRF) immunoconjugate ([89Zr]Zr-DFO-anti-MT1-MMP-IRDye800CW) that targets MT1-MMP, a matrix metalloproteinase overexpressed in high-grade sarcomas. [89Zr]Zr-DFO-anti-MT1-MMP-IRDye800CW was synthesized via site-specific chemoenzymatic glycan modification, characterized, and isolated in high specific activity and radiochemical purity. Saturation binding and immunoreactivity assays indicated only minor perturbation of binding properties. A novel mouse model of dedifferentiated chondrosarcoma based on intrafemoral inoculation of HT1080 WT or KO cells (high and low MT1-MMP expression, respectively) was used to evaluate target binding and biodistribution. Fluorescence and Cerenkov luminescence images of [89Zr]Zr-DFO-anti-MT1-MMP-IRDye800CW showed preferential uptake in HT1080 WT tumors. Ex vivo gamma counting revealed that uptake in MT1-MMP-positive tumors was significantly higher than that in control groups. Taken together, [89Zr]Zr-DFO-anti-MT1-MMP-IRDye800CW is a promising dual-modal sarcoma imaging agent for pre-operative surgical planning and intraoperative surgical guidance.
Author(s): Pringle TA, Chan CD, Luli S, Blair HJ, Rankin KS, Knight JC
Publication type: Article
Publication status: Published
Journal: Bioconjugate Chemistry
Year: 2022
Volume: 33
Issue: 8
Pages: 1564-1573
Print publication date: 17/08/2022
Online publication date: 22/07/2022
Acceptance date: 11/07/2022
Date deposited: 01/08/2022
ISSN (print): 1043-1802
ISSN (electronic): 1520-4812
Publisher: American Chemical Society
URL: https://doi.org/10.1021/acs.bioconjchem.2c00306
DOI: 10.1021/acs.bioconjchem.2c00306
Altmetrics provided by Altmetric